Rgenix to Present Poster on RGX-202 at the 2018 AACR Annual Meeting

NEW YORK–(BUSINESS WIRE)–#AACR18–Rgenix, Inc., a clinical stage biopharmaceutical company developing
first-in-class small molecule and antibody cancer therapeutics,
announced today that Isabel Kurth, PhD, Vice President of Research at
Rgenix, will present a poster about Rgenix’s RGX-202 program at the 2018
American Association for Cancer Research Annual Meeting. The meeting is
scheduled to take place Saturday, April 14 through Wednesday, April 18
in Chicago.

The details of Rgenix’s presentation are as follows:

Event: AACR Annual Meeting 2018

Date: April 18, 2018

Time: 8:00 A.M. – 12:00 P.M. CDT

Description: Poster 5863/10, “RGX-202, a first-in-class
small-molecule inhibitor of the creatine transporter SLC6a8, is a robust
suppressor of cancer growth and metastatic progression”

Location: Section 39, McCormick Place, 2301 S. King Drive,
Chicago, Il. 60616

Dr. Kurth will present data from pre-clinical research of RGX-202, a
first-in-class small molecule inhibitor of the creatine transporter
SLC6a8.

About Rgenix

Rgenix, Inc., is a privately-held clinical-stage biopharmaceutical
company focused on the discovery and development of novel cancer drugs
that target key pathways in cancer progression. The company is pursuing
several first-in-class drug candidates to treat cancers of high unmet
need. Rgenix identifies novel cancer targets using a microRNA based
target discovery platform originally developed by Rgenix’s scientific
co-founders at The Rockefeller University and now exclusively licensed
to Rgenix. The company brings together distinguished scientific
founders, a seasoned Board, and a leadership team comprised of
experienced drug developers. The company is funded by leading
biotechnology investors, including Novo A/S, Sofinnova Partners, and
Alexandria Venture Investments. For more information, please visit www.rgenix.com.

About RGX-202

RGX-202 is a small molecule that inhibits a novel cancer metabolism
pathway involved in supplying energy to cancer cells. The target of
RGX-202, SLC6a8, is over-expressed in several prevalent cancer types,
including gastrointestinal malignancies. RGX-202 has demonstrated
anti-tumor activity in pre-clinical studies, both as a single agent as
well as in combination with standard-of-care therapies. IND-enabling
studies for RGX-202 have been completed in preparation for clinical
development.

Contacts

Media:
RooneyPartners
Marion Janic, 212-223-4017
mjanic@rooneyco.com